STERIS (STE) 10-Q 8 Feb 23 2023 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information Document - shares	9 Months Ended
	Dec. 31, 2022	Feb. 03, 2023
Entity Information [Line Items]
Entity Registrant Name	STERIS plc
Entity Central Index Key	0001757898
Document Type	10-Q
Document Period End Date	Dec. 31, 2022
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--03-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		99,284,443
Entity Small Business	false
Entity Emerging Growth Company	false
Entity File Number	001-38848
Entity Incorporation, State or Country Code	L2
Entity Tax Identification Number	98-1455064
Local Phone Number	1 232 2000
City Area Code	353
Document Transition Report	false
Document Quarterly Report	true
Entity Address, Address Line One	70 Sir John Rogerson's Quay,
Entity Address, City or Town	Dublin 2,
Entity Address, Country	IE
Entity Address, Postal Zip Code	D02 R296
Entity Shell Company	false
STE Two700 Senior Notes Due2031 Member
Entity Information [Line Items]
Title of 12(b) Security	2.700% Senior Notes due 2031
Trading Symbol	STE/31
Security Exchange Name	NYSE
Two700 Senior Notes Due2051 Member
Entity Information [Line Items]
Title of 12(b) Security	3.750% Senior Notes due 2051
Trading Symbol	STE/51
Security Exchange Name	NYSE
Ordinary Shares
Entity Information [Line Items]
Title of 12(b) Security	Ordinary Shares, $0.001 par value
Trading Symbol	STE
Security Exchange Name	NYSE

CONSOLIDATED BALANCE SHEETS (un

CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Dec. 31, 2022	Mar. 31, 2022
Current assets:
Cash and cash equivalents	$ 259,371	$ 348,320
Accounts receivable (net of allowances of $25,137 and $24,371, respectively)	822,758	799,041
Inventories, net	694,357	574,999
Prepaid expenses and other current assets	200,140	156,637
Total current assets	1,976,626	1,878,997
Property, plant, and equipment, net	1,671,157	1,552,576
Operating Lease, Right-of-Use Asset	187,320	188,480
Goodwill	3,853,009	4,404,343
Intangible Assets, Net (Excluding Goodwill)	3,031,456	3,328,537
Other assets	80,356	70,661
Total assets	10,799,924	11,423,594
Current liabilities:
Accounts payable	242,491	225,737
Accrued income taxes	25,226	26,873
Accrued payroll and other related liabilities	130,741	183,721
Capital Lease Obligations, Current	34,954	36,472
Short-term Debt	60,000	142,875
Accrued expenses and other	303,045	306,544
Total current liabilities	796,457	922,222
Long-term indebtedness	3,001,575	2,945,481
Deferred Income Taxes and Other Tax Liabilities, Noncurrent	724,648	780,619
Capital Lease Obligations, Noncurrent	155,978	155,056
Other Liabilities, Noncurrent	72,746	75,579
Total liabilities	4,751,404	4,878,957
Commitments and contingencies (see Note 8)
Common shares, with $0.001 par value; 500,000 authorized; 99,401 shares issued; and 100,067 shares outstanding	4,631,703	4,742,920
Retained earnings	1,770,772	1,999,244
Accumulated other comprehensive income	(364,163)	(209,808)
Total shareholders' equity	6,038,312	6,532,356
Noncontrolling interest	10,208	12,281
Total equity	6,048,520	6,544,637
Total liabilities and equity	$ 10,799,924	$ 11,423,594

CONSOLIDATED BALANCE SHEETS (_2

CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Dec. 31, 2022	Mar. 31, 2022
Statement of Financial Position [Abstract]
Common Stock, Par or Stated Value Per Share	$ 0.001
Common Stock, Shares Authorized	500,000
Common Stock, Shares, Outstanding	99,401	100,067
Allowance for Doubtful Accounts Receivable, Current	$ 25,137	$ 24,371

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Revenues	$ 1,215,994	$ 1,208,971	$ 3,573,002	$ 3,374,378
Cost of revenues:
Total cost of revenues	694,497	670,857	2,001,372	1,929,638
Gross Profit	521,497	538,114	1,571,630	1,444,740
Operating expenses:
Selling, general, and administrative	305,141	310,564	962,962	1,049,116
Goodwill impairment loss	0	0	490,565	0
Research and development	25,514	24,824	75,193	61,847
Restructuring Costs	39	(207)	127	17
Total operating expenses	330,694	335,181	1,528,847	1,110,980
Income from operations	190,803	202,933	42,783	333,760
Non-operating expenses, net:
Interest expense	28,559	22,971	77,356	67,820
Fair value adjustment related to convertible debt liability	0	0	0	27,806
Interest income and miscellaneous expense	1,906	(2,447)	3,200	(4,905)
Total non-operating expenses, net	30,465	20,524	80,556	90,721
Income before income tax expense	160,338	182,409	(37,773)	243,039
Income tax expense	37,013	39,315	43,378	52,222
Net Income	123,325	143,094	(81,151)	190,817
Less: Net Income Attributable to Noncontrolling Interest	(503)	(529)	(956)	(810)
Net Income (Loss) Attributable to Shareholders	$ 123,828	$ 143,623	$ (80,195)	$ 191,627
Net income per common share [Abstract]
Basic	$ 1.24	$ 1.44	$ (0.80)	$ 1.98
Diluted	1.24	1.42	(0.80)	1.97
Cash dividends declared per common share outstanding	$ 0.47	$ 0.43	$ 1.37	$ 1.26
Product [Member]
Revenues:
Revenues	$ 679,042	$ 697,256	$ 1,982,512	$ 1,871,773
Cost of revenues:
Cost of Goods and Services Sold	374,729	373,793	1,058,663	1,072,683
Service [Member]
Revenues:
Revenues	536,952	511,715	1,590,490	1,502,605
Cost of revenues:
Cost of Goods and Services Sold	$ 319,768	$ 297,064	$ 942,709	$ 856,955

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Net Income	$ 123,325	$ 143,094	$ (81,151)	$ 190,817
Less: Net Income Attributable to Noncontrolling Interest	(503)	(529)	(956)	(810)
Net Income (Loss) Attributable to Shareholders	123,828	143,623	(80,195)	191,627
Other comprehensive (loss) income
Amortization of pension and postretirement benefits plans costs, (net of taxes of ($8), $174, ($24) and $523, respectively)	27	(507)	83	(1,521)
Change in cumulative foreign current translation adjustment	233,958	(30,638)	(154,438)	(74,114)
Total other comprehensive (loss) income	233,985	(31,145)	(154,355)	(75,635)
Comprehensive income	$ 357,813	$ 112,478	$ (234,550)	$ 115,992

CONSOLIDATED STATEMENTS OF CO_2

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Statement of Comprehensive Income [Abstract]
Amortization of pension and postretirement benefits plans costs, tax	$ (8)	$ 174	$ (24)	$ 523

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, depletion, and amortization	$ 410,693	$ 319,273
Deferred income taxes	(62,797)	3,141
Share-based compensation	29,857	47,909
(Gain) loss on the disposal of property, plant, and equipment, and intangibles, net	653	863
Loss on sale of businesses, net	3,939	893
Fair value adjustment related to convertible debt liability	0	27,806
Amortization of inventory fair value adjustments	2,477	86,665
Goodwill impairment loss	490,565	0
Other items	4,433	(1,520)
Changes in operating assets and liabilities, net of effects of acquisitions:
Accounts receivable, net	(32,878)	21,493
Inventories, net	(130,434)	(92,138)
Other current assets	(46,116)	(63,393)
Accounts payable	18,819	(11,053)
Accruals and other, net	(66,912)	(17,676)
Net cash provided by operating activities	541,148	513,080
Investing activities:
Purchases of property, plant, equipment, and intangibles, net	(290,520)	(214,491)
Proceeds from the sale of property, plant, equipment, and intangibles	12,164	1,709
Proceeds from Divestiture of Businesses, Net of Cash Divested	6,624	0
Acquisition of businesses, net of cash acquired	(34,020)	(547,353)
Net cash used in investing activities	(305,752)	(760,135)
Financing activities:
Proceeds from Issuance of Senior Long-term Debt	0	1,350,000
Proceeds from Issuance of Secured Debt	0	650,000
Repayments of Senior Debt	(91,000)	(721,284)
Repayments of Convertible Debt	0	(371,361)
Repayments of Secured Debt	(141,875)	(125,000)
Proceeds (Payments) under credit facilities, net	216,561	(203,805)
Deferred financing fees and debt issuance costs	0	(17,247)
Acquisition related deferred or contingent consideration	(310)	(32,583)
Repurchases of ordinary shares	(153,952)	(27,628)
Cash dividends paid to ordinary shareholders	(136,898)	(120,118)
Payments to Noncontrolling Interests	(794)	(997)
Proceeds from issuance of equity to minority shareholders	0	3,672
Proceeds from (Payments for) Other Financing Activities	1,497	6,789
Net cash used in financing activities	(306,771)	390,438
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations	(17,574)	(4,825)
Increase (decrease) in cash and cash equivalents	(88,949)	138,558
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents	259,371	359,089
Net Income	$ (81,151)	$ 190,817

CONSOLIDATED STATEMENT OF SHARE

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY Statement - USD ($) shares in Thousands, $ in Thousands	Total	Noncontrolling Interest [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Common Stock [Member]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 3,891,468	$ 10,478	$ (61,243)	$ 1,939,408	$ 2,002,825
Shares, Issued					85,353
Net Income (Loss) Attributable to Parent	191,627			191,627
Net Income (Loss) Attributable to Noncontrolling Interest	(810)	(810)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	190,817
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(75,635)		(75,635)
Treasury Stock, Shares, Acquired					225
Payments for Repurchase of Common Stock	27,628			21,047	$ 6,581
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					686
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	54,465				$ 54,465
Dividends, Common Stock, Cash	120,118			120,118
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest	3,672	3,672
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	997	997
Increase (Decrease) In Noncontrolling Interests, Other	135	135
Stock Issued During Period, Shares, Acquisitions					14,297
Stock Issued During Period, Value, Acquisitions	2,689,317				$ 2,689,317
Consideration related to equity component of Cantel Convertible Debt	175,555				175,555
Consideration Related to Cantel Equity Compensation Programs	18,173				18,173
Reclassification to Cantel convertible debt, premium liability	$ (175,555)				$ (175,555)
Common Stock, Dividends, Per Share, Cash Paid	$ 1.26
Net Income (Loss) Attributable to Parent	$ 191,627			191,627
Net Income (Loss) Attributable to Noncontrolling Interest	(810)	(810)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	190,817
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(75,635)		(75,635)
Treasury Stock, Shares, Acquired					(225)
Payments for Repurchase of Common Stock	(27,628)			(21,047)	$ (6,581)
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					686
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	54,465				$ 54,465
Dividends, Common Stock, Cash	(120,118)			(120,118)
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	997	997
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	6,544,931	9,287	(105,733)	1,893,196	$ 4,748,181
Shares, Issued					99,911
Net Income (Loss) Attributable to Parent	143,623			143,623
Net Income (Loss) Attributable to Noncontrolling Interest	(529)	(529)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	143,094
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(31,145)		(31,145)
Treasury Stock, Shares, Acquired					95
Payments for Repurchase of Common Stock	2,877			3,938	$ (1,061)
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					295
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	8,957				$ 8,957
Dividends, Common Stock, Cash	43,011			43,011
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest	3,672	3,672
Increase (Decrease) In Noncontrolling Interests, Other	$ 48	48
Common Stock, Dividends, Per Share, Cash Paid	$ 0.43
Net Income (Loss) Attributable to Parent	$ 143,623			143,623
Net Income (Loss) Attributable to Noncontrolling Interest	(529)	(529)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	143,094
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(31,145)		(31,145)
Treasury Stock, Shares, Acquired					(95)
Payments for Repurchase of Common Stock	(2,877)			(3,938)	$ 1,061
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					295
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	8,957				$ 8,957
Dividends, Common Stock, Cash	(43,011)			(43,011)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	6,623,669
Stockholders' Equity Attributable to Parent			(136,878)	1,989,870	$ 4,758,199
Noncontrolling interest		12,478
Shares, Issued					100,111
Stockholders' Equity Attributable to Parent			(136,878)	1,989,870	$ 4,758,199
Stockholders' Equity Attributable to Noncontrolling Interest		12,478
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	6,544,637	12,281	(209,808)	1,999,244	$ 4,742,920
Stockholders' Equity Attributable to Parent	6,532,356
Noncontrolling interest	12,281
Shares, Issued					100,067
Stockholders' Equity Attributable to Parent	6,532,356
Stockholders' Equity Attributable to Noncontrolling Interest	12,281
Net Income (Loss) Attributable to Parent	(80,195)			(80,195)
Net Income (Loss) Attributable to Noncontrolling Interest	(956)	(956)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	(81,151)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(154,355)		(154,355)
Treasury Stock, Shares, Acquired					850
Payments for Repurchase of Common Stock	153,952			11,379	$ 142,573
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					183
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	31,356				$ 31,356
Dividends, Common Stock, Cash	136,898			136,898
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	794	794
Increase (Decrease) In Noncontrolling Interests, Other	$ (323)	(323)
Common Stock, Dividends, Per Share, Cash Paid	$ 1.37
Net Income (Loss) Attributable to Parent	$ (80,195)			(80,195)
Net Income (Loss) Attributable to Noncontrolling Interest	(956)	(956)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	(81,151)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(154,355)		(154,355)
Treasury Stock, Shares, Acquired					(850)
Payments for Repurchase of Common Stock	(153,952)			(11,379)	$ (142,573)
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					183
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	31,356				$ 31,356
Dividends, Common Stock, Cash	(136,898)			(136,898)
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	794	794
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	5,813,447	11,390	(598,148)	1,695,087	$ 4,705,118
Shares, Issued					99,868
Net Income (Loss) Attributable to Parent	123,828			123,828
Net Income (Loss) Attributable to Noncontrolling Interest	(503)	(503)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	123,325
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	233,985		233,985
Treasury Stock, Shares, Acquired					493
Payments for Repurchase of Common Stock	84,030			1,226	$ 82,804
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					25
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	9,389				$ 9,389
Dividends, Common Stock, Cash	46,917			46,917
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	794	794
Increase (Decrease) In Noncontrolling Interests, Other	$ 115	115
Common Stock, Dividends, Per Share, Cash Paid	$ 0.47
Net Income (Loss) Attributable to Parent	$ 123,828			123,828
Net Income (Loss) Attributable to Noncontrolling Interest	(503)	(503)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	123,325
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	233,985		233,985
Treasury Stock, Shares, Acquired					(493)
Payments for Repurchase of Common Stock	(84,030)			(1,226)	$ (82,804)
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					25
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	9,389				$ 9,389
Dividends, Common Stock, Cash	(46,917)			(46,917)
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	794	794
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	6,048,520
Stockholders' Equity Attributable to Parent	6,038,312		(364,163)	1,770,772	$ 4,631,703
Noncontrolling interest	10,208	10,208
Shares, Issued					99,400
Stockholders' Equity Attributable to Parent	6,038,312		$ (364,163)	$ 1,770,772	$ 4,631,703
Stockholders' Equity Attributable to Noncontrolling Interest	$ 10,208	$ 10,208

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies(Notes)	9 Months Ended
	Dec. 31, 2022
Notes To Financial Statements [Abstract]
Significant Accounting Policies	Nature of Operations and Summary of Significant Accounting Policies STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare, life sciences and dental products and services. We offer our Customers a unique mix of innovative consumable products, such as detergents, gastrointestinal (“GI”) endoscopy accessories, barrier product solutions, and other products and services, including: equipment installation and maintenance, microbial reduction of medical devices, dental instruments and tools, instrument and scope repair, laboratory testing services, outsourced reprocessing, and capital equipment products, such as sterilizers and surgical tables, automated endoscope reprocessors, and connectivity solutions such as operating room (“OR”) integrati on. We operate and report in four reportable business segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. We describe our business segments in Note 9 titled "Business Segment Information." Our fiscal year ends on March 31. References in this Quarterly Report to a particular “year” or “year-end” mean our fiscal year. The significant accounting policies applied in preparing the accompanying consolidated financial statements of the Company are summarized below: Interim Financial Statements We prepared the accompanying unaudited consolidated financial statements of the Company according to accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. This means that they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Our unaudited interim consolidated financial statements contain all material adjustments (including normal recurring accruals and adjustments) management believes are necessary to fairly state our financial condition, results of operations, and cash flows for the periods presented. These interim consolidated financial statements should be read together with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended March 31, 2022, which was filed with the Securities and Exchange Commission ("SEC") on May 31, 2022. The Consolidated Balance Sheet at March 31, 2022 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Principles of Consolidation We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's consolidated financial statements. Use of Estimates We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three and nine month periods ended December 31, 2022 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2023. Revenue Recognition and Associated Liabilities Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers. We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets. In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately. Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year. We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less. Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At December 31, 2022, assets related to costs to fulfill a contract were not material to our consolidated financial statements. Refer to Note 9 titled, "Business Segment Information" for disaggregation of revenue. Product Revenue Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer or Group Purchasing Organization ("GPO") agreement. We recognize revenue for sales of product when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to capital equipment products is deferred until installation is complete if the capital equipment and installation are highly integrated and form a single performance obligation. Service Revenue Within our Healthcare and Life Sciences segments, service revenues include revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer, or Group Purchasing Organization ("GPO") agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. Healthcare service revenues also include outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair. We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair our products over the duration of the contract. Generally, these contract terms are cancellable without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as service revenue ratably over the contract term using a time-based input measure. Within our Applied Sterilization Technologies segment, service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement and revenues are generally recognized upon completion of the service. Contract Liabilities Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During the first nine months of fiscal 2023, $76,861 of the March 31, 2022 deferred revenue balance was recorded as revenue. During the first nine months of fiscal 2022, $42,942 of the March 31, 2021 deferred revenue balance was recorded as revenue. Refer to Note 6 titled, "Additional Consolidated Balance Sheet Information" for deferred revenue balances. Service Liabilities Payments received in advance of performance for cancellable preventive maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract. Refer to Note 6 titled, "Additional Consolidated Balance Sheet Information" for service liability balances. Remaining Performance Obligations Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include capital equipment and consumable orders which have not shipped. With regard to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services. As of December 31, 2022, the transaction price allocated to remaining performance obligations was approximately $1,592,000. We expect to recognize approximately 63% of the transaction price within one year and approximately 29% beyond one year. The remainder has yet to be scheduled for delivery. Recently Issued Accounting Standards Impacting the Company Recently Issued Accounting Standards Impacting the Company are presented in the following table: Standard Date of Issuance Description Date of Adoption Effect on the financial statements or other significant matters Standards that have been adopted in fiscal 2023 ASU 2021-08 "Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers." October 2021 The standard provides guidance to improve the accounting for acquired revenue contracts with Customers in a business combination by addressing diversity in practice and inconsistency related to the recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer. First Quarter Fiscal 2023 We adopted this standard effective April 1, 2022 with no material impact to our consolidated financial statements. A detailed description of our significant and critical accounting policies, estimates, and assumptions is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2022, which was filed with the SEC on May 31, 2022. Our significant and critical accounting policies, estimates, and assumptions have not changed materially from March 31, 2022.

Business Acquisitions and Dives

Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Notes)	9 Months Ended
	Dec. 31, 2022
Business Acquisitions and Divestitures [Abstract]
Business Combination Disclosure	Business Acquisitions During the first nine months of fiscal 2023, we completed several tuck-in acquisitions which continued to expand our product and service offerings in the Applied Sterilization Technologies and Healthcare segments. Total aggregate consideration was approximately $40,720, including potential contingent consideration of $6,700. On June 2, 2021, we acquired all outstanding equity interests in Cantel Medical LLC ("Cantel") through a U.S. subsidiary. The total consideration for Cantel common stock and s tock equivalents was $3,599,471. We funded the cash portion of the transaction consideration and repayment of a significant amount of Cantel’s existing debt obligations with a portion of the proceeds from new debt, which is described in our Annual Report on Form 10-K for the year ended March 31, 2022, which was filed with the SEC on May 31, 2022. In addition to the total purchase consideration, STERIS assumed and repaid $721,284 of existing Cantel debt obligations and assumed Cantel's obligations associated with convertible senior notes issued on May 15, 2020, which is described in our Annual Report on Form 10-K for the year ended March 31, 2022, which was filed with the SEC on May 31, 2022. Fair Value of Assets Acquired and Liabilities Assumed The table below presents the allocation of fair values of assets acquired and liabilities assumed on the acquisition date. March 31, 2022 (As previously reported) Adjustments Final Cash $ 169,073 $ — $ 169,073 Accounts receivable 172,226 — 172,226 Inventory 249,221 — 249,221 Property, plant, and equipment 267,360 (1,282) 266,078 Lease right-of-use assets, net 59,720 — 59,720 Other assets 72,864 — 72,864 Intangible assets 2,942,000 — 2,942,000 Goodwill 1,522,381 22,088 1,544,469 Total assets acquired 5,454,845 20,806 5,475,651 Convertible debt, par value 168,000 — 168,000 Other current liabilities 247,549 5,595 253,144 Long-term lease obligations 47,856 — 47,856 Deferred income taxes, net 670,685 15,211 685,896 Long-term indebtedness 721,284 — 721,284 Total liabilities assumed 1,855,374 20,806 1,876,180 Net assets acquired $ 3,599,471 $ — $ 3,599,471 Acquisition and integration expenses totaled $4,817 and $18,493 for the three and nine months ended December 31, 2022 , respectively. Acquisition and integration expenses totaled $9,298 and $167,698 for the three and nine months ended December 31, 2021 , respectively. These costs were primarily related to the acquisition and integration of Cantel. Acquisition and integration expenses are reported in the Selling, general and administrative expenses line of our Consolidated Statements of Income and include but are not limited to investment banker, advisory, legal, other professional fees, and certain employee-related expenses. During the second quarter of fiscal 2023, in connection with the preparation of our quarterly consolidated financial statements, we identified and recognized a goodwill impairment loss of $490,565 related to goodwill that arose with respect to assets acquired in the Cantel acquisition. For more information on the impairment loss, see Note 17 to our consolidated financial statements titled, "Goodwill." For more information on the acquisition of Cantel, refer to our Annual Report on Form 10-K for the year ended March 31, 2022, which was filed with the SEC on May 31, 2022.

Inventories, Net (Notes)

Inventories, Net (Notes)	9 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventories, Net	Inventories, Net Inventories are stated at the lower of their cost and net realizable value determined by the first-in, first-out (“FIFO”) cost method. Inventory costs include material, labor, and overhead . Inventories, net consisted of the following: December 31, March 31, Raw materials $ 233,313 $ 195,035 Work in process 103,898 76,021 Finished goods 399,034 334,880 Reserve for excess and obsolete inventory (41,888) (30,937) Inventories, net $ 694,357 $ 574,999

Property, Plant and Equipment (

Property, Plant and Equipment (Notes)	9 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant, and Equipment Information related to the major categories of our depreciable assets is as follows: December 31, March 31, Land and land improvements (1) $ 83,262 $ 84,015 Buildings and leasehold improvements 674,484 654,851 Machinery and equipment 952,350 903,649 Information systems 234,297 222,620 Radioisotope 621,526 597,641 Construction in progress (1) 489,772 356,013 Total property, plant, and equipment 3,055,691 2,818,789 Less: accumulated depreciation and depletion (1,384,534) (1,266,213) Property, plant, and equipment, net $ 1,671,157 $ 1,552,576 (1) Land is not depreciated. Construction in progress is not depreciated until placed in service.

Debt (Notes)

Debt (Notes)	9 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Debt	Debt Indebtedness was as follows: December 31, March 31, Short-term debt Term Loan, current portion $ 27,500 $ 27,500 Delayed Draw Term Loan, current portion 32,500 24,375 Private Placement Senior Notes — 91,000 Total short-term debt $ 60,000 $ 142,875 Long-term debt Private Placement Senior Notes $ 746,118 $ 758,726 Revolving Credit Facility 274,658 58,908 Deferred financing costs (22,326) (25,278) Term Loan 51,875 177,500 Delayed Draw Term Loan 601,250 625,625 Senior Public Notes 1,350,000 1,350,000 Total long-term debt $ 3,001,575 $ 2,945,481 Total debt $ 3,061,575 $ 3,088,356 Additional information regarding our indebtedness is included in the notes to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2022, which was filed with the SEC on May 31, 2022.

Additional Consolidated Balance

Additional Consolidated Balance Sheets Information (Notes)	9 Months Ended
	Dec. 31, 2022
Notes To Financial Statements [Abstract]
Additional Consolidated Balance Sheets Information	Additional Consolidated Balance Sheet Information Additional information related to our Consolidated Balance Sheets is as follows: December 31, March 31, Accrued payroll and other related liabilities: Compensation and related items $ 65,965 $ 71,878 Accrued vacation/paid time off 14,567 13,669 Accrued bonuses 25,345 64,702 Accrued employee commissions 21,515 30,171 Other postretirement benefit obligations-current portion 1,190 1,190 Other employee benefit plans obligations-current portion 2,159 2,111 Total accrued payroll and other related liabilities $ 130,741 $ 183,721 Accrued expenses and other: Deferred revenues $ 100,232 $ 110,791 Service liabilities 57,963 51,365 Self-insured risk reserves-current portion 15,878 8,995 Accrued dealer commissions 32,300 31,700 Accrued warranty 13,442 14,108 Asset retirement obligation-current portion 581 1,181 Accrued interest 18,306 10,014 Other 64,343 78,390 Total accrued expenses and other $ 303,045 $ 306,544 Other liabilities: Self-insured risk reserves-long-term portion $ 19,213 $ 19,213 Other postretirement benefit obligations-long-term portion 6,807 7,335 Defined benefit pension plans obligations-long-term portion 3,836 1,772 Other employee benefit plans obligations-long-term portion 1,094 1,360 Accrued long-term income taxes 10,068 12,225 Asset retirement obligation-long-term portion 19,691 12,362 Other 12,037 21,312 Total other liabilities $ 72,746 $ 75,579

Income Tax Expense (Notes)

Income Tax Expense (Notes)	9 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Tax Expense	Income Tax Expense The effective income tax rates for the three month periods ended December 31, 2022 and 2021 were 23.1% and 21.6%, respectively. The higher fiscal 2023 effective tax rate is the result of changes in geographic mix and favorable discrete items in the third quarter of fiscal 2022. The effective income tax rates for the nine month periods ended December 31, 2022 and 2021 were (114.8)% and 21.5%, respectively. The fiscal 2023 effective tax rate for the nine month period ended December 31, 2022 decreased when compared to the prior year period, primarily due to the tax impact of the goodwill impairment loss recognized on the Dental segment during the second quarter of fiscal 2023. Income tax expense is provided on an interim basis based upon our estimate of the annual effective income tax rate, adjusted each quarter for discrete items. In determining the estimated annual effective income tax rate, we analyze various factors, including projections of our annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, our ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives. We operate in numerous taxing jurisdictions and are subject to regular examinations by various United States federal, state and local, as well as foreign jurisdictions. We are no longer subject to United States federal examinations for years before fiscal 2018 and, with limited exceptions, we are no longer subject to United States state and local, or non-United States, income tax examinations by tax authorities for years before fiscal 2016. We remain subject to tax authority audits in various jurisdictions wherever we do business. In the fourth quarter of fiscal 2021, we completed an appeals process with the U.S. Internal Revenue Service (the “IRS”) regarding proposed audit adjustments related to deductibility of interest paid on intercompany debt for fiscal years 2016 and 2017. An agreement was reached on final interest rates, which also impacts subsequent years through 2020. We estimate the total federal, state, and local tax impact of the settlement to be approximately $12,000 for the fiscal years 2016 through 2020, of which approximately $7,500 has been paid through December 31, 2022. In May 2021, we received two notices of proposed tax adjustment from the IRS regarding deemed dividend inclusions and associated withholding tax. The notices relate to the fiscal and calendar year 2018. The IRS adjustments would result in a cumulative tax liability of approximately $50,000. We are contesting the IRS’s assertions. We have not established reserves related to these notices. An unfavorable outcome is not expected to have a material adverse impact on our consolidated financial position but could be material to our consolidated results of operations and cash flows for any one period.

Contingencies (Notes)

Contingencies (Notes)	9 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Commitments and Contingencies We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, gases, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), commercial claims (e.g., breach of contract, economic loss, warranty, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief. We believe we have adequately reserved for our current litigation and claims that are probable and estimable, and further believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse effect on our consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome or effect of current or future litigation, investigations, claims or other proceedings (including without limitation the matters discussed below). For certain types of claims, we presently maintain insurance coverage for personal injury and property damage and other liability coverages in amounts and with deductibles that we believe are prudent, but there can be no assurance that these coverages will be applicable or adequate to cover adverse outcomes of claims or legal proceedings against us. Civil, criminal, regulatory or other proceedings involving our products or services could possibly result in judgments, settlements or administrative or judicial decrees requiring us, among other actions, to pay damages or fines or effect recalls, or be subject to other governmental, Customer or other third party claims or remedies, which could materially effect our business, performance, prospects, value, financial condition, and results of operations. For additional information regarding these matters, see the following portions of our Annual Report on Form 10-K for the year ended March 31, 2022, which was filed with the SEC on May 31, 2022, Item 1 titled "Business - Information with respect to our Business in General - Government Regulation" and the "Risk Factors" in Item 1A titled "Product and service related regulations and claims." From time to time, STERIS is also involved in legal proceedings as a plaintiff involving contract, patent protection, and other claims asserted by us. Gains, if any, from these proceedings are recognized when they are realized. We are subject to taxation from United States federal, state and local, and non-U.S. jurisdictions. Tax positions are settled primarily through the completion of audits within each individual jurisdiction or the closing of statutes of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. We describe income taxes further in Note 7 to our consolidated financial statements titled, “Income Tax Expense” in this Quarterly Report on Form 10-Q.

Business Segment Information (N

Business Segment Information (Notes)	9 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Business Segment Information	Business Segment Information We report our financial information in four reportable business segments: Healthcare, Applied Sterilization Technologies, Life Sciences and Dental. Non-allocated operating costs that support the entire Company and items not indicative of operating trends are excluded from segment operating income. Our Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. Our products and services range from infection prevention consumables and capital equipment, as well as services to maintain that equipment; to the repair of re-usable procedural instruments; to outsourced instrument reprocessing services. In addition, our procedural solutions also include single-use devices and capital equipment infrastructure used primarily in operating rooms, ambulatory surgery centers, endoscopy suites, and other procedural areas. Our Applied Sterilization Technologies ("AST") segment is a third-party service provider for contract sterilization, as well as testing services needed to validate sterility services for medical device and pharmaceutical manufacturers. Our technology-neutral offering supports Customers every step of the way, from testing through sterilization. Our Life Sciences segment provides a comprehensive offering of products and services that support pharmaceutical manufacturing, primarily for vaccine and other biopharma Customers focused on aseptic manufacturing. These solutions include a full suite of consumable products, equipment maintenance and specialty services, and capital equipment. Our Dental segment provides a comprehensive offering for dental practitioners and dental schools, offering instruments, infection prevention consumables and instrument management systems. We disclose a measure of segment income that is consistent with the way management operates and views the business. The accounting policies for reportable segments are the same as those for the consolidated Company. Certain prior period costs were reallocated from the Healthcare segment to Corporate to conform with current year presentation. The prior period segment operating income measure has been recast for comparability. For the three and nine months e nded December 31, 2022 , revenues from a single Customer did not represent ten percent or more of the Healthcare, AST or Life Sciences segment revenues. Three Customers collectively and consistently account for more than 40.0% of our Dental segment revenue. The percentage associated with these three Customers collectively in any one period may vary due to the buying patterns of these three Customers as well as other Dental Customers. These three Customers collectively accounted for appr oxi mately 47.2% and 43.8% o f our Dental segment revenues for the three and nine months ended December 31, 2022, respectively. These three Customers collectively accounted for appr oxi mately 55.8% and 46.1% o f our Dental segment revenues for the three and nine months ended December 31, 2021, respectively. A dditional information regarding our segments is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2022, which was filed with the SEC on May 31, 2022. Financial information for each of our segments is presented in the following table: Three Months Ended December 31, Nine Months Ended December 31, 2022 2021 2022 2021 Revenues: Healthcare $ 769,144 $ 759,675 $ 2,200,483 $ 2,106,626 Applied Sterilization Technologies 222,014 216,298 675,283 630,092 Life Sciences 121,273 127,908 379,248 381,706 Dental 103,563 105,090 317,988 255,954 Total revenues $ 1,215,994 $ 1,208,971 $ 3,573,002 $ 3,374,378 Segment operating income (loss): Healthcare $ 175,399 $ 175,778 $ 497,233 $ 482,487 Applied Sterilization Technologies 103,539 101,343 323,238 303,059 Life Sciences 45,249 52,032 149,173 158,639 Dental 20,337 23,096 67,992 65,607 Corporate (53,873) (62,360) (196,872) (219,131) Total segment operating income $ 290,651 $ 289,889 $ 840,764 $ 790,661 Less: Adjustments Amortization of acquired intangible assets (1) $ 93,941 $ 75,021 $ 281,727 $ 191,552 Acquisition and integration related charges (2) 4,817 9,298 18,493 167,698 Tax restructuring costs (3) 282 118 533 228 (Gain) on fair value adjustment of acquisition related contingent consideration (1) — — (3,100) — Net (gain) loss on divestiture of businesses (1) (838) 489 3,939 893 Amortization of inventory and property "step up" to fair value (1) 1,608 2,237 5,697 96,513 Restructuring charges (4) 38 (207) 127 17 Goodwill impairment loss (5) — — 490,565 — Total income from operations $ 190,803 $ 202,933 $ 42,783 $ 333,760 (1) For more information regarding our recent acquisitions and divestitures, refer to Note 2 titled, "Business Acquisitions and Divestitures" included in our Annual Report on Form 10-K for the year ended March 31, 2022, which was filed with the SEC on May 31, 2022. (2) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions. (3) Costs incurred in tax restructuring. (4) For more information regarding our restructuring efforts, refer to our Annual R eport on Form 10-K for the year ended March 31, 2022, which was filed with the SEC on May 31, 2022. (5) For more information regarding our goodwill impairment loss, see Note 17 to our consolidated financial statements titled, "Goodwill." Additional information regarding our fiscal 2023 and fiscal 2022 revenue is disclosed in the following tables: Three Months Ended December 31, Nine Months Ended December 31, 2022 2021 2022 2021 Healthcare: Capital equipment $ 227,226 $ 217,214 $ 618,844 570,509 Consumables 259,810 273,750 757,892 750,531 Service 282,108 268,711 823,747 785,586 Total Healthcare Revenues $ 769,144 $ 759,675 $ 2,200,483 $ 2,106,626 Applied Sterilization Technologies Service Revenues $ 222,014 $ 216,298 $ 675,283 $ 630,092 Life Sciences: Capital equipment $ 28,581 $ 30,412 $ 99,095 $ 97,343 Consumables 55,610 61,096 172,587 179,380 Service 37,082 36,400 107,566 104,983 Total Life Sciences Revenues $ 121,273 $ 127,908 $ 379,248 $ 381,706 Dental Revenues $ 103,563 $ 105,090 $ 317,988 $ 255,954 Total Revenues $ 1,215,994 $ 1,208,971 $ 3,573,002 $ 3,374,378 Three Months Ended December 31, Nine Months Ended December 31, 2022 2021 2022 2021 Revenues: Ireland $ 17,959 $ 20,086 $ 53,130 $ 62,077 United States 883,390 851,292 2,589,472 2,383,039 Other locations 314,645 337,593 930,400 929,262 Total Revenues $ 1,215,994 $ 1,208,971 $ 3,573,002 $ 3,374,378

Shares and Preferred Shares (No

Shares and Preferred Shares (Notes)	9 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Earnings Per Share	Shares and Preferred Shares Ordinary shares We calculate basic earnings per share based upon the weighted average number of shares outstanding. We calculate diluted earnings per share based upon the weighted average number of shares outstanding plus the dilutive effect of share equivalents calculated using the treasury stock method. The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share: Three Months Ended December 31, Nine Months Ended December 31, Denominator (shares in thousands): 2022 2021 2022 2021 Weighted average shares outstanding—basic 99,716 100,038 99,922 96,679 Dilutive effect of share equivalents (1) 450 788 — 823 Weighted average shares outstanding and share equivalents—diluted 100,166 100,826 99,922 97,502 (1) The dilutive effect of share equivalents is excluded from the calculation of diluted earnings per share for the nine months ended December 31, 2022 due to our net loss for that period. Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive: Three Months Ended December 31, Nine Months Ended December 31, (shares in thousands) 2022 2021 2022 2021 Number of share options 797 271 577 251 Additional Authorized Shares The Company has an additional authorized share capital of 50,000,000 preferred shares of $0.001 par value each, plus 25,000 deferred ordinary shares of €1.00 par value each, in order to satisfy minimum statutory capital requirements for all Irish public limited companies.

Equity

Equity	9 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Treasury Stock	Repurchases of Ordinary Shares On May 7, 2019, our Board of Directors authorized a share repurchase program resulting in a share repurchase authorization of approximately $78,979 (net of taxes, fees and commissions). On July 30, 2019, our Board of Directors approved an increase in the May 7, 2019 authorization of an additional amount of $300,000 (net of taxes, fees and commissions). As of December 31, 2022, there was approximately $160,626 (net of taxes, fees and commissions) of remaining availability under the Board authorized share repurchase program. The share repurchase program has no specified expiration date. Under the authorization, the Company may repurchase its shares from time to time through open market purchases, including 10b5-1 plans. Any share repurchases may be activated, suspended or discontinued at any time. Due to the uncertainty surrounding the COVID-19 pandemic, share repurchases were suspended on April 9, 2020. The suspension was lifted effective February 10, 2022, enabling the Company to resume stock repurchases pursuant to the prior authorizations. During the first nine months of fiscal 2023, we repurchased 775,320 of our ordinary shares for the aggregate amount of $148,306 (net of fees and commissions) pursuant to the authorizations.

Share-Based Compensation (Notes

Share-Based Compensation (Notes)	9 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	Share-Based Compensation We maintain a long-term ince ntive plan that makes available shares for grants, at the discretion of the Board of Directors or the Compensation and Organizational Development Committee of the Board of Directors, to officers, directors, and key employees in the form of stock options, restricted shares, restricted share units, stock appreciation rights and share grants. We satisfy share award incentives through the issuance of new ordinary shares. Stock options provide the right to purchase our shares at the market price on the date of grant, or for options granted to employees in fiscal 2019 and thereafter, 110% of the market price on the date of grant, subject to the terms of the plan and agreements. Generally, one-fourth of the stock options granted to employees become exercisable for each full year of employment following the grant date. Stock options granted generally expire 10 years after the grant date, or in some cases earlier if the option holder is no longer employed by us. Restricted shares and restricted share units generally cliff vest after a four year period or vest in tranches of one-fourth of the number granted for each year of employment after the grant date. As of December 31, 2022, 2,798,121 ordinary shares remained available for grant under the long-term incentive plan. The fair value of stock option awards was estimated at their grant date using the Black-Scholes-Merton option pricing model. This model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable, characteristics that are not present in our option grants. If the model permitted consideration of the unique characteristics of employee stock options, the resulting estimate of the fair value of the stock options could be different. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in our Consolidated Statements of Income. The expense is classified as cost of goods sold or selling, general and administrative expenses in a manner consistent with the employee’s compensation and benefits. The following weighted average assumptions were used for options granted during the first nine months of fiscal 2023 and 2022: Fiscal 2023 Fiscal 2022 Risk-free interest rate 2.44 % 1.10 % Expected life of options 5.9 years 5.9 years Expected dividend yield of stock 0.80 % 0.95 % Expected volatility of stock 24.49 % 24.27 % The risk-free interest rate is based upon the U.S. Treasury yield curve. The expected life of options is reflective of historical experience, vesting schedules and contractual terms. The expected dividend yield of stock represents our best estimate of the expected future dividend yield. The expected volatility of stock is derived by referring to our historical stock prices over a time frame similar to that of the expected life of the grant. An estimated forfeiture rate of 2.54% and 2.85% was applied in fiscal 2023 and 2022, respectively. This rate is calculated based upon historical activity and represents an estimate of the granted options not expected to vest. If actual forfeitures differ from this calculated rate, we may be required to make additional adjustments to compensation expense in future periods. The assumptions used above are reviewed at the time of each significant option grant, or at least annually. A summary of share option activity is as follows: Number of Weighted Average Aggregate Outstanding at March 31, 2022 1,560,954 $ 138.37 Granted 235,435 247.45 Exercised (25,228) 51.70 Forfeited (8,928) 205.25 Outstanding at December 31, 2022 1,762,233 $ 153.85 6.4 years $ 77,486 Exercisable at December 31, 2022 1,137,168 $ 121.60 5.4 years $ 74,465 We estimate that 611,629 of the non-vested stock options outstanding at December 31, 2022 will ultimately vest. The aggregate intrinsic value in the table above represents the total pre-tax difference between the $184.69 closing price of our ordinary shares on December 31, 2022 over the exercise prices of the stock options, multiplied by the number of options outstanding or outstanding and exercisable, as applicable. The aggregate intrinsic value is not recorded for financial accounting purposes and the value changes daily based on the daily changes in the fair market value of ordinary shares. The total intrinsic value of stock options exercised during the first nine months of fiscal 2023 and fiscal 2022 was $4,638 and $43,425, respectively. Net cash proceeds from the exercise of stock options were $1,497 and $6,789 for the first nine months of fiscal 2023 and fiscal 2022, respectively. The weighted average grant date fair value of stock option grants was $50.72 and $37.52 for the first nine months of fiscal 2023 and fiscal 2022, respectively. Stock appreciation rights (“SARS”) carry generally the same terms and vesting requirements as stock options except that they are settled in cash upon exercise and therefore, are classified as liabilities. As of May 24, 2021, we no longer have outstanding SARS. A summary of the non-vested restricted share and share unit activity is presented below: Number of Number of Restricted Share Units Weighted Average Non-vested at March 31, 2022 485,510 33,677 $ 157.37 Granted 126,974 13,030 225.07 Vested (146,056) (13,189) 126.98 Forfeited (15,681) (2,120) 181.75 Non-vested at December 31, 2022 450,747 31,398 $ 186.24 Restricted shares and restricted share unit grants are valued based on the closing stock price at the grant date. The value of restricted shares and units that vested during the first nine months of fiscal 2023 at the time of grant was $20,237. As of December 31, 2022, there was a total of $72,008 in unrecognized compensation cost related to non-vested share-based compensation granted under our share-based compensation plan. We expect to recognize the cost over a weighted average period of 2.1 years. Cantel Share Based Compensation Plan In connection with the acquisition of Cantel, outstanding, non-vested Cantel restricted share units were replaced with STERIS restricted share units. A total of 280,402 STERIS restricted share units replaced Cantel awards based on a ratio of one Cantel restricted share unit to 0.4262 STERIS restricted share units. Cantel time based restricted share units were replaced with STERIS restricted share units with the same three-year pro-rata vesting terms based on the original award date. Performance based Cantel restricted share units were replaced with time based STERIS restricted share units that vest pro rata over the remaining one, two or three anniversaries from the original Cantel award date. The number of Cantel performance restricted share units was replaced based on the original target achievement level. All replacement restricted share units retained dividend accumulation rights. The fair value of each STERIS restricted share unit awarded on June 2, 2021 to replace outstanding non-vested Cantel restricted share units was $191.18 based on the closing price of STERIS ordinary shares on June 2, 2021. Approximately $18,173 of the total $53,607 grant date fair value was attributable to pre-acquisition services provided and was recorded as a component of purchase consideration in connection with the acquisition of Cantel. Recognition of unamortized share-based compensation expense totaling $18,545 was accelerated in connection with the planned termination of certain Cantel executive level employees in the first quarter of fiscal 2022 . As a result of the formal notices provided and the terms of the Cantel share based compensati on plans and Cantel Executive Severance and Change of Control Plan, the remaining service required under the awards became non-substantive requiri ng acceleration of the remaining related compensation cost. As of December 31, 2022, there was a total of $2,319 in unrecognized compensation cost related to non-vested STERIS restricted shar e units awarded to replace Cantel restricted share units. We expect to recognize the cost over a weighted average period of 0.8 years . A summary of the non-vested restricted share units activity associated with the Cantel share-based compensation plans is presented below: Number of Restricted Share Units Weighted Average Non-vested at March 31, 2022 45,722 $ 191.18 Granted — — Vested (24,775) 191.18 Forfeited (4,507) 191.18 Non-vested at December 31, 2022 16,440 $ 191.18

Financial and Other Guarantees(

Financial and Other Guarantees(Notes)	9 Months Ended
	Dec. 31, 2022
Product Warranties Disclosures [Abstract]
Product Warranty Disclosure	Financial and Other Guarantees We generally offer a limited parts and labor warranty on capital equipment. The specific terms and conditions of those warranties vary depending on the product sold and the countries where we conduct business. We record a liability for the estimated cost of product warranties at the time product revenues are recognized. The amounts we expect to incur on behalf of our Customers for the future estimated cost of these warranties are recorded as a current liability on the accompanying Consolidated Balance Sheets. Factors that affect the amount of our warranty liability include the number and type of installed units, historical and anticipated rates of product failures, and material and service costs per claim. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary. Changes in our warranty liability during the first nine months of fiscal 2023 were as follows: Warranties Balance at March 31, 2022 $ 14,108 Warranties issued during the period 8,749 Settlements made during the period (9,415) Balance at December 31, 2022 $ 13,442

Deritvatives and Hedging (Notes

Deritvatives and Hedging (Notes)	9 Months Ended
	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities Disclosure	Derivatives and Hedging From time to time, we enter into forward contracts to hedge potential foreign currency gains and losses that arise from transactions denominated in foreign currencies, including inter-company transactions. We may also enter into commodity swap contracts to hedge price changes in nickel that impact raw materials included in our cost of revenues. During the third quarter of fiscal 2023, we also held forward foreign currency contracts to hedge a portion of our expected non-U.S. dollar-denominated earnings against our reporting currency, the U.S. dollar. These foreign currency exchange contracts will mature during fiscal 2023. We did not elect hedge accounting for these forward foreign currency contracts; however, we may seek to apply hedge accounting in future scenarios. We do not use derivative financial instruments for speculative purposes. None of these contracts are designated as hedging instruments and do not receive hedge accounting treatment; therefore, changes in their fair value are not deferred but are recognized immediately in the Consolidated Statements of Income. At December 31, 2022, we held foreign currency forward contracts to buy 13.0 million British pounds sterling; and to sell 150.0 million Mexican pesos, and 16.3 million euros. At December 31, 2022, we held commodity swap contracts to buy 200.4 thousand pounds of nickel. Asset Derivatives Liability Derivatives Fair Value at Fair Value at Fair Value at Fair Value at Balance sheet location December 31, 2022 March 31, 2022 December 31, 2022 March 31, 2022 Prepaid & other $ 842 $ 2,780 $ — $ — Accrued expenses and other $ — $ — $ 326 $ 198 The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income: Location of gain (loss) Amount of gain (loss) recognized in income Three Months Ended December 31, Nine Months Ended December 31, 2022 2021 2022 2021 Foreign currency forward contracts Selling, general and administrative $ 952 $ 1,707 $ 5,581 $ 4,279 Commodity swap contracts Cost of revenues $ 1,189 $ 417 $ (1,994) $ 1,110

Fair Value Measurements (Notes)

Fair Value Measurements (Notes)	9 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Disclosures	. Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. We estimate the fair value of financial assets and liabilities using available market information and generally accepted valuation methodologies. The inputs used to measure fair value are classified into three tiers. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the entity to develop its own assumptions. The following table shows the fair value of our financial assets and liabilities at December 31, 2022 and March 31, 2022: Fair Value Measurements Carrying Value Quoted Prices Significant Other Significant Level 1 Level 2 Level 3 December 31, March 31, December 31, March 31, December 31, March 31, December 31, March 31, Assets: Cash and cash equivalents $ 259,371 $ 348,320 $ 259,371 $ 348,320 $ — $ — $ — $ — Forward and swap contracts (1) 842 2,780 — — 842 2,780 — — Equity investments (2) 6,820 8,520 6,820 8,520 — — — — Other investments 2,178 2,272 2,178 2,272 — — — — Liabilities: Forward and swap contracts (1) $ 326 $ 198 $ — $ — $ 326 $ 198 $ — $ — Deferred compensation plans (2) 955 1,240 955 1,240 — — — — Debt (3) 3,061,575 3,088,356 — — 2,693,782 2,991,680 — — Contingent consideration obligations (4) 14,820 10,550 — — — — 14,820 10,550 (1) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates. (2) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the "Interest and miscellaneous expense (income) line" of the Consolidated Statement of Income. During the third quarter and first nine months of fiscal 2023, we recorded gains (losses) of $(342) and $1,385, respectively, related to these investments. During the third quarter and first nine months of fiscal 2022, we recorded gains (losses) of $28 and $(200), respectively, related to these investments. (3) We estimate the fair value of our debt using discounted cash flow analyses, based on estimated current incremental borrowing rates for similar types of borrowing arrangement s. (4) Contingent consideration obligations arise from business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and capture the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates. The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at December 31, 2022 are summarized as follows: Contingent Consideration Balance at March 31, 2022 $ 10,550 Additions 7,450 Payments (60) Reductions (3,100) Currency translation adjustments (20) Balance at December 31, 2022 $ 14,820

Reclassifications out of Accumu

Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Notes)	9 Months Ended
	Dec. 31, 2022
Reclassifications out of AOCI [Abstract]
Comprehensive Income (Loss) Note [Text Block]	Reclassifications Out of Accumulated Other Comprehensive Income (Loss) Amounts in Accumulated Other Comprehensive Income (Loss) are presented net of the related tax. Currency Translation is not adjusted for income taxes. Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three and nine months ended December 31, 2022 and 2021 were as follows: Defined Benefit Plans (1) Currency Translation (2) Total Accumulated Other Comprehensive Income (Loss) Three Months Nine Months Three Months Nine Months Three Months Nine Months Beginning Balance $ 1,332 $ 1,276 $ (599,480) $ (211,084) $ (598,148) $ (209,808) Other Comprehensive Income (Loss) before reclassifications 138 431 233,958 (154,438) 234,096 (154,007) Amounts reclassified from Accumulated Other Comprehensive Income (Loss) (111) (348) — — (111) (348) Net current-period Other Comprehensive (Loss) 27 83 233,958 (154,438) 233,985 (154,355) Balance at December 31, 2022 $ 1,359 $ 1,359 $ (365,522) $ (365,522) $ (364,163) $ (364,163) (1) The amortization (gain) of defined benefit pension items is reported in the Interest and miscellaneous expense (income) line of our Consolidated Statements of Income. (2) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income. Defined Benefit Plans (1) Currency Translation (2) Total Accumulated Other Comprehensive Income (Loss) Three Months Nine Months Three Months Nine Months Three Months Nine Months Beginning Balance $ (6,533) $ (5,519) $ (99,200) $ (55,724) $ (105,733) $ (61,243) Other Comprehensive Income before reclassifications 575 1,751 (30,638) (74,114) (30,063) (72,363) Amounts reclassified from Accumulated Other Comprehensive Income (Loss) (1,082) (3,272) — — (1,082) (3,272) Net current-period Other Comprehensive Income (Loss) (507) (1,521) (30,638) (74,114) (31,145) (75,635) Balance at December 31, 2021 $ (7,040) $ (7,040) $ (129,838) $ (129,838) $ (136,878) $ (136,878) 1) The amortization (gain) of defined benefit pension items is reported in the Interest and miscellaneous expense (income) line of our Consolidated Statements of Income.

Intangible Assets, Goodwill and

Intangible Assets, Goodwill and Other	9 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill Disclosure	Goodwill Changes to the carrying amount of goodwill for the nine months ended December 31, 2022 are as follows: Healthcare Segment Life Sciences Segment Applied Sterilization Technologies Segment Dental Segment Total Balance at March 31, 2022 $ 2,326,830 $ 179,288 $ 1,432,858 $ 465,367 $ 4,404,343 Goodwill acquired 10,753 — — — 10,753 Measurement period adjustments to acquired goodwill (21,624) 3,147 — 40,565 22,088 Impairment — — — (490,565) (490,565) Divestiture (2,358) — — — (2,358) Foreign currency translation adjustments (18,157) (1,073) (56,655) (15,367) (91,252) Balance at December 31, 2022 $ 2,295,444 $ 181,362 $ 1,376,203 $ — $ 3,853,009 We evaluate the recoverability of recorded goodwill annually at the reporting unit level during the third fiscal quarter, or when indicators of potential impairment exist. The Company's reporting units are equivalent to the reportable operating segments. In connection with the preparation of our second quarter consolidated financial statements, we considered the risk of impairment due to deteriorating macroeconomic conditions including rising interest rates and inflationary pressures on material and labor costs, as well as uncertainty regarding the impact such economic strains will have on patient and Customer behavior in the short-term. Our conclusion, based on the qualitative assessment of these factors, was that it was more likely than not that the goodwill allocated to the Dental segment as of September 30, 2022 was impaired. Our quantitative analysis to measure the extent of goodwill impairment compared the estimated fair value to the carrying value of the Dental segment. The fair value is estimated as the present value of future cash flows. Future cash flow projections are consistent with those used in our forecasting and strategic planning processes. The determination of the discount rate requires judgement and assumptions to be developed about the weighted average cost of capital that market participants would employ in evaluating the current fair value of the business. The macroeconomic factors that triggered the interim review are also the drivers of the increase in the weighted average cost of capital assumption. In connection with the preparation of our second quarter consolidated financial statements, we identified and recognized, as of September 30, 2022, that the estimated fair value of the Dental segment was below the carrying value resulting in a non-cash goodwill impairment charge of $490,565. The impairment charge was recorded within “Goodwill impairment loss” in the Consolidated Statements of Income during the three-month period ended September 30, 2022. Our review as of September 30, 2022 did not indicate that impairment of goodwill was more likely than not for any of the remaining segments during the period. The annual goodwill impairment review was conducted in the third quarter of fiscal 2023 as planned. No additional goodwill impairment was identified during this review.

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies Accounting Policies (Policies)	9 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's consolidated financial statements.
Use of Estimates	Use of Estimates We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three and nine month periods ended December 31, 2022 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2023.
Revenue	Revenue Recognition and Associated Liabilities Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers. We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets. In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately. Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year. We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less. Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At December 31, 2022, assets related to costs to fulfill a contract were not material to our consolidated financial statements. Refer to Note 9 titled, "Business Segment Information" for disaggregation of revenue. Product Revenue Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer or Group Purchasing Organization ("GPO") agreement. We recognize revenue for sales of product when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to capital equipment products is deferred until installation is complete if the capital equipment and installation are highly integrated and form a single performance obligation. Service Revenue Within our Healthcare and Life Sciences segments, service revenues include revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer, or Group Purchasing Organization ("GPO") agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. Healthcare service revenues also include outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair. We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair our products over the duration of the contract. Generally, these contract terms are cancellable without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as service revenue ratably over the contract term using a time-based input measure. Within our Applied Sterilization Technologies segment, service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement and revenues are generally recognized upon completion of the service. Contract Liabilities Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During the first nine months of fiscal 2023, $76,861 of the March 31, 2022 deferred revenue balance was recorded as revenue. During the first nine months of fiscal 2022, $42,942 of the March 31, 2021 deferred revenue balance was recorded as revenue. Refer to Note 6 titled, "Additional Consolidated Balance Sheet Information" for deferred revenue balances. Service Liabilities Payments received in advance of performance for cancellable preventive maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract. Refer to Note 6 titled, "Additional Consolidated Balance Sheet Information" for service liability balances. Remaining Performance Obligations Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include capital equipment and consumable orders which have not shipped. With regard to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services.

Accounting Policies (Tables)

Accounting Policies (Tables)	9 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
New Accounting Pronouncement, Early Adoption	Recently Issued Accounting Standards Impacting the Company are presented in the following table: Standard Date of Issuance Description Date of Adoption Effect on the financial statements or other significant matters Standards that have been adopted in fiscal 2023 ASU 2021-08 "Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers." October 2021 The standard provides guidance to improve the accounting for acquired revenue contracts with Customers in a business combination by addressing diversity in practice and inconsistency related to the recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer. First Quarter Fiscal 2023 We adopted this standard effective April 1, 2022 with no material impact to our consolidated financial statements.

Business Acquisitions and Div_2

Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Tables)	9 Months Ended
	Dec. 31, 2022
Business Acquisitions and Divestitures [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The table below presents the allocation of fair values of assets acquired and liabilities assumed on the acquisition date. March 31, 2022 (As previously reported) Adjustments Final Cash $ 169,073 $ — $ 169,073 Accounts receivable 172,226 — 172,226 Inventory 249,221 — 249,221 Property, plant, and equipment 267,360 (1,282) 266,078 Lease right-of-use assets, net 59,720 — 59,720 Other assets 72,864 — 72,864 Intangible assets 2,942,000 — 2,942,000 Goodwill 1,522,381 22,088 1,544,469 Total assets acquired 5,454,845 20,806 5,475,651 Convertible debt, par value 168,000 — 168,000 Other current liabilities 247,549 5,595 253,144 Long-term lease obligations 47,856 — 47,856 Deferred income taxes, net 670,685 15,211 685,896 Long-term indebtedness 721,284 — 721,284 Total liabilities assumed 1,855,374 20,806 1,876,180 Net assets acquired $ 3,599,471 $ — $ 3,599,471

Inventories, Net Inventories, N

Inventories, Net Inventories, Net (Tables)	9 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory	December 31, March 31, Raw materials $ 233,313 $ 195,035 Work in process 103,898 76,021 Finished goods 399,034 334,880 Reserve for excess and obsolete inventory (41,888) (30,937) Inventories, net $ 694,357 $ 574,999

Property, Plant and Equipment P

Property, Plant and Equipment Property, Plant and Equipment (Tables)	9 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Information related to the major categories of our depreciable assets is as follows: December 31, March 31, Land and land improvements (1) $ 83,262 $ 84,015 Buildings and leasehold improvements 674,484 654,851 Machinery and equipment 952,350 903,649 Information systems 234,297 222,620 Radioisotope 621,526 597,641 Construction in progress (1) 489,772 356,013 Total property, plant, and equipment 3,055,691 2,818,789 Less: accumulated depreciation and depletion (1,384,534) (1,266,213) Property, plant, and equipment, net $ 1,671,157 $ 1,552,576 (1) Land is not depreciated. Construction in progress is not depreciated until placed in service.

Debt Debt (Tables)

Debt Debt (Tables)	9 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Schedule of Debt	Indebtedness was as follows: December 31, March 31, Short-term debt Term Loan, current portion $ 27,500 $ 27,500 Delayed Draw Term Loan, current portion 32,500 24,375 Private Placement Senior Notes — 91,000 Total short-term debt $ 60,000 $ 142,875 Long-term debt Private Placement Senior Notes $ 746,118 $ 758,726 Revolving Credit Facility 274,658 58,908 Deferred financing costs (22,326) (25,278) Term Loan 51,875 177,500 Delayed Draw Term Loan 601,250 625,625 Senior Public Notes 1,350,000 1,350,000 Total long-term debt $ 3,001,575 $ 2,945,481 Total debt $ 3,061,575 $ 3,088,356

Additional Consolidated Balan_2

Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Tables)	9 Months Ended
	Dec. 31, 2022
Notes To Financial Statements [Abstract]
Additional Consolidated Balance Sheets Information	Additional Consolidated Balance Sheet Information Additional information related to our Consolidated Balance Sheets is as follows: December 31, March 31, Accrued payroll and other related liabilities: Compensation and related items $ 65,965 $ 71,878 Accrued vacation/paid time off 14,567 13,669 Accrued bonuses 25,345 64,702 Accrued employee commissions 21,515 30,171 Other postretirement benefit obligations-current portion 1,190 1,190 Other employee benefit plans obligations-current portion 2,159 2,111 Total accrued payroll and other related liabilities $ 130,741 $ 183,721 Accrued expenses and other: Deferred revenues $ 100,232 $ 110,791 Service liabilities 57,963 51,365 Self-insured risk reserves-current portion 15,878 8,995 Accrued dealer commissions 32,300 31,700 Accrued warranty 13,442 14,108 Asset retirement obligation-current portion 581 1,181 Accrued interest 18,306 10,014 Other 64,343 78,390 Total accrued expenses and other $ 303,045 $ 306,544 Other liabilities: Self-insured risk reserves-long-term portion $ 19,213 $ 19,213 Other postretirement benefit obligations-long-term portion 6,807 7,335 Defined benefit pension plans obligations-long-term portion 3,836 1,772 Other employee benefit plans obligations-long-term portion 1,094 1,360 Accrued long-term income taxes 10,068 12,225 Asset retirement obligation-long-term portion 19,691 12,362 Other 12,037 21,312 Total other liabilities $ 72,746 $ 75,579
Schedule of Accrued Liabilities [Table Text Block]	Additional information related to our Consolidated Balance Sheets is as follows: December 31, March 31, Accrued payroll and other related liabilities: Compensation and related items $ 65,965 $ 71,878 Accrued vacation/paid time off 14,567 13,669 Accrued bonuses 25,345 64,702 Accrued employee commissions 21,515 30,171 Other postretirement benefit obligations-current portion 1,190 1,190 Other employee benefit plans obligations-current portion 2,159 2,111 Total accrued payroll and other related liabilities $ 130,741 $ 183,721 Accrued expenses and other: Deferred revenues $ 100,232 $ 110,791 Service liabilities 57,963 51,365 Self-insured risk reserves-current portion 15,878 8,995 Accrued dealer commissions 32,300 31,700 Accrued warranty 13,442 14,108 Asset retirement obligation-current portion 581 1,181 Accrued interest 18,306 10,014 Other 64,343 78,390 Total accrued expenses and other $ 303,045 $ 306,544 Other liabilities: Self-insured risk reserves-long-term portion $ 19,213 $ 19,213 Other postretirement benefit obligations-long-term portion 6,807 7,335 Defined benefit pension plans obligations-long-term portion 3,836 1,772 Other employee benefit plans obligations-long-term portion 1,094 1,360 Accrued long-term income taxes 10,068 12,225 Asset retirement obligation-long-term portion 19,691 12,362 Other 12,037 21,312 Total other liabilities $ 72,746 $ 75,579

Business Segment Information Bu

Business Segment Information Business Segment Information (Tables)	9 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Financial information for each of our segments is presented in the following table: Three Months Ended December 31, Nine Months Ended December 31, 2022 2021 2022 2021 Revenues: Healthcare $ 769,144 $ 759,675 $ 2,200,483 $ 2,106,626 Applied Sterilization Technologies 222,014 216,298 675,283 630,092 Life Sciences 121,273 127,908 379,248 381,706 Dental 103,563 105,090 317,988 255,954 Total revenues $ 1,215,994 $ 1,208,971 $ 3,573,002 $ 3,374,378 Segment operating income (loss): Healthcare $ 175,399 $ 175,778 $ 497,233 $ 482,487 Applied Sterilization Technologies 103,539 101,343 323,238 303,059 Life Sciences 45,249 52,032 149,173 158,639 Dental 20,337 23,096 67,992 65,607 Corporate (53,873) (62,360) (196,872) (219,131) Total segment operating income $ 290,651 $ 289,889 $ 840,764 $ 790,661 Less: Adjustments Amortization of acquired intangible assets (1) $ 93,941 $ 75,021 $ 281,727 $ 191,552 Acquisition and integration related charges (2) 4,817 9,298 18,493 167,698 Tax restructuring costs (3) 282 118 533 228 (Gain) on fair value adjustment of acquisition related contingent consideration (1) — — (3,100) — Net (gain) loss on divestiture of businesses (1) (838) 489 3,939 893 Amortization of inventory and property "step up" to fair value (1) 1,608 2,237 5,697 96,513 Restructuring charges (4) 38 (207) 127 17 Goodwill impairment loss (5) — — 490,565 — Total income from operations $ 190,803 $ 202,933 $ 42,783 $ 333,760
Revenue from External Customers by Products and Services [Table Text Block]	Three Months Ended December 31, Nine Months Ended December 31, 2022 2021 2022 2021 Healthcare: Capital equipment $ 227,226 $ 217,214 $ 618,844 570,509 Consumables 259,810 273,750 757,892 750,531 Service 282,108 268,711 823,747 785,586 Total Healthcare Revenues $ 769,144 $ 759,675 $ 2,200,483 $ 2,106,626 Applied Sterilization Technologies Service Revenues $ 222,014 $ 216,298 $ 675,283 $ 630,092 Life Sciences: Capital equipment $ 28,581 $ 30,412 $ 99,095 $ 97,343 Consumables 55,610 61,096 172,587 179,380 Service 37,082 36,400 107,566 104,983 Total Life Sciences Revenues $ 121,273 $ 127,908 $ 379,248 $ 381,706 Dental Revenues $ 103,563 $ 105,090 $ 317,988 $ 255,954 Total Revenues $ 1,215,994 $ 1,208,971 $ 3,573,002 $ 3,374,378
Revenue from External Customers by Geographic Areas [Table Text Block]	Three Months Ended December 31, Nine Months Ended December 31, 2022 2021 2022 2021 Revenues: Ireland $ 17,959 $ 20,086 $ 53,130 $ 62,077 United States 883,390 851,292 2,589,472 2,383,039 Other locations 314,645 337,593 930,400 929,262 Total Revenues $ 1,215,994 $ 1,208,971 $ 3,573,002 $ 3,374,378

Shares and Preferred Shares Sha

Shares and Preferred Shares Shares and Preferred Shares (Tables)	9 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Schedule of Weighted Average Number of Shares [Table Text Block]	Three Months Ended December 31, Nine Months Ended December 31, Denominator (shares in thousands): 2022 2021 2022 2021 Weighted average shares outstanding—basic 99,716 100,038 99,922 96,679 Dilutive effect of share equivalents (1) 450 788 — 823 Weighted average shares outstanding and share equivalents—diluted 100,166 100,826 99,922 97,502 (1) The dilutive effect of share equivalents is excluded from the calculation of diluted earnings per share for the nine months ended December 31, 2022 due to our net loss for that period.
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive: Three Months Ended December 31, Nine Months Ended December 31, (shares in thousands) 2022 2021 2022 2021 Number of share options 797 271 577 251

Share-Based Compensation Share-

Share-Based Compensation Share-Based Compensation (Tables)	9 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Assumptions Used	The following weighted average assumptions were used for options granted during the first nine months of fiscal 2023 and 2022: Fiscal 2023 Fiscal 2022 Risk-free interest rate 2.44 % 1.10 % Expected life of options 5.9 years 5.9 years Expected dividend yield of stock 0.80 % 0.95 % Expected volatility of stock 24.49 % 24.27 %
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding	A summary of share option activity is as follows: Number of Weighted Average Aggregate Outstanding at March 31, 2022 1,560,954 $ 138.37 Granted 235,435 247.45 Exercised (25,228) 51.70 Forfeited (8,928) 205.25 Outstanding at December 31, 2022 1,762,233 $ 153.85 6.4 years $ 77,486 Exercisable at December 31, 2022 1,137,168 $ 121.60 5.4 years $ 74,465
Share-based Compensation Arrangements by Share-based Payment Award, Restricted Stock Units, Vested and Expected to Vest	A summary of the non-vested restricted share and share unit activity is presented below: Number of Number of Restricted Share Units Weighted Average Non-vested at March 31, 2022 485,510 33,677 $ 157.37 Granted 126,974 13,030 225.07 Vested (146,056) (13,189) 126.98 Forfeited (15,681) (2,120) 181.75 Non-vested at December 31, 2022 450,747 31,398 $ 186.24
Share-based Payment Arrangement, Activity	A summary of the non-vested restricted share units activity associated with the Cantel share-based compensation plans is presented below: Number of Restricted Share Units Weighted Average Non-vested at March 31, 2022 45,722 $ 191.18 Granted — — Vested (24,775) 191.18 Forfeited (4,507) 191.18 Non-vested at December 31, 2022 16,440 $ 191.18

Financial and Other Guarantees

Financial and Other Guarantees Financial and Other Gurantees (Tables)	9 Months Ended
	Dec. 31, 2022
Product Warranties Disclosures [Abstract]
Schedule of Product Warranty Liability	Changes in our warranty liability during the first nine months of fiscal 2023 were as follows: Warranties Balance at March 31, 2022 $ 14,108 Warranties issued during the period 8,749 Settlements made during the period (9,415) Balance at December 31, 2022 $ 13,442

Derivatives and Hedging Derivat

Derivatives and Hedging Derivatives and Hedging (Tables)	9 Months Ended
	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	Asset Derivatives Liability Derivatives Fair Value at Fair Value at Fair Value at Fair Value at Balance sheet location December 31, 2022 March 31, 2022 December 31, 2022 March 31, 2022 Prepaid & other $ 842 $ 2,780 $ — $ — Accrued expenses and other $ — $ — $ 326 $ 198
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance	The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income: Location of gain (loss) Amount of gain (loss) recognized in income Three Months Ended December 31, Nine Months Ended December 31, 2022 2021 2022 2021 Foreign currency forward contracts Selling, general and administrative $ 952 $ 1,707 $ 5,581 $ 4,279 Commodity swap contracts Cost of revenues $ 1,189 $ 417 $ (1,994) $ 1,110

Fair Value Measurements Fair Va

Fair Value Measurements Fair Value Measurements (Tables)	9 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Option, Disclosures	The following table shows the fair value of our financial assets and liabilities at December 31, 2022 and March 31, 2022: Fair Value Measurements Carrying Value Quoted Prices Significant Other Significant Level 1 Level 2 Level 3 December 31, March 31, December 31, March 31, December 31, March 31, December 31, March 31, Assets: Cash and cash equivalents $ 259,371 $ 348,320 $ 259,371 $ 348,320 $ — $ — $ — $ — Forward and swap contracts (1) 842 2,780 — — 842 2,780 — — Equity investments (2) 6,820 8,520 6,820 8,520 — — — — Other investments 2,178 2,272 2,178 2,272 — — — — Liabilities: Forward and swap contracts (1) $ 326 $ 198 $ — $ — $ 326 $ 198 $ — $ — Deferred compensation plans (2) 955 1,240 955 1,240 — — — — Debt (3) 3,061,575 3,088,356 — — 2,693,782 2,991,680 — — Contingent consideration obligations (4) 14,820 10,550 — — — — 14,820 10,550 (1) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates. (2) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the "Interest and miscellaneous expense (income) line" of the Consolidated Statement of Income. During the third quarter and first nine months of fiscal 2023, we recorded gains (losses) of $(342) and $1,385, respectively, related to these investments. During the third quarter and first nine months of fiscal 2022, we recorded gains (losses) of $28 and $(200), respectively, related to these investments. (3) We estimate the fair value of our debt using discounted cash flow analyses, based on estimated current incremental borrowing rates for similar types of borrowing arrangement s. (4) Contingent consideration obligations arise from business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and capture the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at December 31, 2022 are summarized as follows: Contingent Consideration Balance at March 31, 2022 $ 10,550 Additions 7,450 Payments (60) Reductions (3,100) Currency translation adjustments (20) Balance at December 31, 2022 $ 14,820

Reclassifications out of Accu_2

Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Dec. 31, 2022
Reclassifications out of AOCI [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three and nine months ended December 31, 2022 and 2021 were as follows: Defined Benefit Plans (1) Currency Translation (2) Total Accumulated Other Comprehensive Income (Loss) Three Months Nine Months Three Months Nine Months Three Months Nine Months Beginning Balance $ 1,332 $ 1,276 $ (599,480) $ (211,084) $ (598,148) $ (209,808) Other Comprehensive Income (Loss) before reclassifications 138 431 233,958 (154,438) 234,096 (154,007) Amounts reclassified from Accumulated Other Comprehensive Income (Loss) (111) (348) — — (111) (348) Net current-period Other Comprehensive (Loss) 27 83 233,958 (154,438) 233,985 (154,355) Balance at December 31, 2022 $ 1,359 $ 1,359 $ (365,522) $ (365,522) $ (364,163) $ (364,163) (1) The amortization (gain) of defined benefit pension items is reported in the Interest and miscellaneous expense (income) line of our Consolidated Statements of Income. (2) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income. Defined Benefit Plans (1) Currency Translation (2) Total Accumulated Other Comprehensive Income (Loss) Three Months Nine Months Three Months Nine Months Three Months Nine Months Beginning Balance $ (6,533) $ (5,519) $ (99,200) $ (55,724) $ (105,733) $ (61,243) Other Comprehensive Income before reclassifications 575 1,751 (30,638) (74,114) (30,063) (72,363) Amounts reclassified from Accumulated Other Comprehensive Income (Loss) (1,082) (3,272) — — (1,082) (3,272) Net current-period Other Comprehensive Income (Loss) (507) (1,521) (30,638) (74,114) (31,145) (75,635) Balance at December 31, 2021 $ (7,040) $ (7,040) $ (129,838) $ (129,838) $ (136,878) $ (136,878) 1) The amortization (gain) of defined benefit pension items is reported in the Interest and miscellaneous expense (income) line of our Consolidated Statements of Income.

Intangible Assets, Goodwill a_2

Intangible Assets, Goodwill and Other (Tables)	9 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Changes to the carrying amount of goodwill for the nine months ended December 31, 2022 are as follows: Healthcare Segment Life Sciences Segment Applied Sterilization Technologies Segment Dental Segment Total Balance at March 31, 2022 $ 2,326,830 $ 179,288 $ 1,432,858 $ 465,367 $ 4,404,343 Goodwill acquired 10,753 — — — 10,753 Measurement period adjustments to acquired goodwill (21,624) 3,147 — 40,565 22,088 Impairment — — — (490,565) (490,565) Divestiture (2,358) — — — (2,358) Foreign currency translation adjustments (18,157) (1,073) (56,655) (15,367) (91,252) Balance at December 31, 2022 $ 2,295,444 $ 181,362 $ 1,376,203 $ — $ 3,853,009

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies Revenue Table (Details) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue, Remaining Performance Obligation, Amount	$ 1,592,000
Deferred Revenue, Revenue Recognized	$ 76,861	$ 42,942
Expected recognition within the next year [Member]
Revenue, Remaining Performance Obligation, Percentage	63%
Expected recognition beyond the next year [Member] [Member]
Revenue, Remaining Performance Obligation, Percentage	29%

Business Acquisitions and Div_3

Business Acquisitions and Divestitures Fiscal Acquisitions (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2022
Business Acquisition [Line Items]
Contingent consideration	$ 14,820		$ 14,820		$ 10,550
Gain (Loss) on Disposition of Business	838	$ (489)	(3,939)	$ (893)
Business Combination, Acquisition Related Costs	4,817	9,298	18,493	167,698
Operating Lease, Right-of-Use Asset	187,320		187,320		188,480
Goodwill	3,853,009		3,853,009		4,404,343
Payments to Acquire Businesses, Net of Cash Acquired			34,020	547,353
Goodwill, Purchase Accounting Adjustments			22,088
Cantel Medical Corp.
Business Acquisition [Line Items]
Cash	169,073		169,073		169,073
Accounts receivable	172,226		172,226		172,226
Inventory	249,221		249,221		249,221
Property, plant, and equipment	266,078		266,078		267,360
Operating Lease, Right-of-Use Asset	59,720		59,720		59,720
Other assets	72,864		72,864		72,864
Intangible assets	2,942,000		2,942,000		2,942,000
Goodwill	1,544,469		1,544,469		1,522,381
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets	5,475,651		5,475,651		5,454,845
Business combination, Convertible Debt, Par Value Assumed	168,000		168,000		168,000
Current liabilities	253,144		253,144		247,549
Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation	47,856		47,856		47,856
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities	685,896		685,896		670,685
Business Combination, Long-term Obligations Assumed	721,284	$ 721,284	721,284	721,284	721,284
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	1,876,180		1,876,180		1,855,374
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	3,599,471		3,599,471		$ 3,599,471
Payments to Acquire Businesses, Net of Cash Acquired				$ 3,599,471
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Cash			0
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Accounts Receivable			0
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory			0
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment			(1,282)
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Lease right-of-use assets, net			0
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Other Assets			0
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles			0
Goodwill, Purchase Accounting Adjustments			22,088
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Assets			20,806
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Convertible debt, par value			0
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Other Current Liabilities			5,595
Business Combination Provisional Information Initial Accounting Incomplete ,Adjustment ,Long-term lease obligations			0
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Deferred Income Taxes			15,211
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Long-term indebtedness			0
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Liabilities			20,806
Business Combination Provisional Information Initial Accounting Incomplete Adjustment Net Assets Acquired			0
Other FY 23 Acquisition
Business Acquisition [Line Items]
Contingent consideration	$ 6,700		6,700
Payments to Acquire Businesses, Net of Cash Acquired			$ 40,720

Inventories, Net Inventories,_2

Inventories, Net Inventories, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Mar. 31, 2022
Raw materials	$ 233,313	$ 195,035
Work in process	103,898	76,021
Finished goods	399,034	334,880
Reserve for excess and obsolete inventory	(41,888)	(30,937)
Inventories, net	$ 694,357	$ 574,999

Property, Plant and Equipment_2

Property, Plant and Equipment Property, Plant and Equipment (Details) - USD ($) $ in Thousands		9 Months Ended
		Dec. 31, 2022	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment		Information related to the major categories of our depreciable assets is as follows: December 31, March 31, Land and land improvements (1) $ 83,262 $ 84,015 Buildings and leasehold improvements 674,484 654,851 Machinery and equipment 952,350 903,649 Information systems 234,297 222,620 Radioisotope 621,526 597,641 Construction in progress (1) 489,772 356,013 Total property, plant, and equipment 3,055,691 2,818,789 Less: accumulated depreciation and depletion (1,384,534) (1,266,213) Property, plant, and equipment, net $ 1,671,157 $ 1,552,576 (1) Land is not depreciated. Construction in progress is not depreciated until placed in service.
Property, Plant and Equipment [Line Items]
Land and land improvements	[1]	$ 83,262	$ 84,015
Buildings and leasehold improvements		674,484	654,851
Machinery and equipment		952,350	903,649
Radioisotope		621,526	597,641
Construction in progress	[1]	489,772	356,013
Total property, plant, and equipment		3,055,691	2,818,789
Less: accumulated depreciation and depletion		(1,384,534)	(1,266,213)
Property, plant, and equipment, net		1,671,157	1,552,576
Capitalized Computer Hardware/Software, Gross		$ 234,297	$ 222,620
[1]Land is not depreciated. Construction in progress is not depreciated until placed in service.

Debt Debt (Details)

Debt Debt (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Dec. 31, 2022	Mar. 31, 2022
Debt Disclosure [Abstract]
Schedule of Debt	Indebtedness was as follows: December 31, March 31, Short-term debt Term Loan, current portion $ 27,500 $ 27,500 Delayed Draw Term Loan, current portion 32,500 24,375 Private Placement Senior Notes — 91,000 Total short-term debt $ 60,000 $ 142,875 Long-term debt Private Placement Senior Notes $ 746,118 $ 758,726 Revolving Credit Facility 274,658 58,908 Deferred financing costs (22,326) (25,278) Term Loan 51,875 177,500 Delayed Draw Term Loan 601,250 625,625 Senior Public Notes 1,350,000 1,350,000 Total long-term debt $ 3,001,575 $ 2,945,481 Total debt $ 3,061,575 $ 3,088,356
Debt Instrument [Line Items]
Deferred financing costs	$ 22,326	$ 25,278
Credit Agreement	274,658	58,908
Total long term debt	3,001,575	2,945,481
Debt, Long-term and Short-term, Combined Amount	3,061,575	3,088,356
Short-term Debt	60,000	142,875
Term loan, current portion	27,500	27,500
Term Loan	51,875	177,500
Delayed Draw Term Loan	601,250	625,625
Delayed draw term loan, current portion	$ 32,500	24,375
Common Stock, Par or Stated Value Per Share	$ 0.001
Private Placement
Debt Instrument [Line Items]
Senior Notes, Current	$ 0	91,000
Senior Notes
Debt Instrument [Line Items]
Senior Notes, Noncurrent	1,350,000	1,350,000
Private Placement
Debt Instrument [Line Items]
Senior Notes, Noncurrent	$ 746,118	$ 758,726

Additional Consolidated Balan_3

Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Mar. 31, 2022
Accrued payroll and other related liabilities:
Compensation and related items	$ 65,965	$ 71,878
Accrued vacation/paid time off	14,567	13,669
Accrued bonuses	25,345	64,702
Accrued employee commissions	21,515	30,171
Other postretirement benefit obligations-current portion	1,190	1,190
Other employee benefit plans obligations-current portion	2,159	2,111
Accrued expenses and other:
Deferred revenues	100,232	110,791
Service liabilities	57,963	51,365
Self-insured risk reserves-current portion	15,878	8,995
Accrued dealer commissions	32,300	31,700
Accrued warranty	13,442	14,108
Asset retirement obligation-current portion	581	1,181
Other	64,343	78,390
Total accrued expenses and other	303,045	306,544
Other liabilities:
Self-insured risk reserves-long-term portion	19,213	19,213
Other postretirement benefit obligations-long-term portion	6,807	7,335
Defined benefit pension plans obligations-long-term portion	3,836	1,772
Other employee benefit plans obligations-long-term portion	1,094	1,360
Accrued long-term income taxes	10,068	12,225
Asset retirement obligation-long-term portion	19,691	12,362
Long-term liabilities, other	12,037	21,312
Other Liabilities, Noncurrent	72,746	75,579
Employee-related Liabilities, Current	130,741	183,721
Accrued interest	$ 18,306	$ 10,014

Income Tax Expense Income Tax E

Income Tax Expense Income Tax Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Effective Income Tax Rate, Continuing Operations	23.10%	21.60%	(114.80%)	21.50%
Uncertain Tax Liability Resulting From IRS Notice	$ 50,000		$ 50,000
Income Tax Examination, Estimate of Possible Loss			12,000
Income tax examination, amount of loss paid			$ 7,500

Business Segment Information _2

Business Segment Information Business Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2022
Segment Reporting Information [Line Items]
Revenues	$ 1,215,994	$ 1,208,971	$ 3,573,002	$ 3,374,378
Segment operating income	190,803	202,933	42,783	333,760
Restructuring Charges	38	(207)	127	17
Goodwill impairment loss	0	0	490,565	0
Amortization of acquired intangible assets	93,941	75,021	281,727	191,552
Business Combination, Acquisition Related Costs	4,817	9,298	18,493	167,698
loss (gain) on fair value contingent consideration adjustments	0	0	(3,100)	0
Impact of TCJA	282	118	533	228
Net loss on divestiture of businesses	(838)	489	3,939	893
Amortization of inventory and property step-up to fair value	1,608	2,237	5,697	96,513
Assets	10,799,924		10,799,924		$ 11,423,594
Property, Plant and Equipment, Net	1,671,157		1,671,157		$ 1,552,576
Life Sciences
Segment Reporting Information [Line Items]
Revenues	121,273	127,908	379,248	381,706
Segment operating income	45,249	52,032	149,173	158,639
Applied Sterilization Technologies
Segment Reporting Information [Line Items]
Revenues	222,014	216,298	675,283	630,092
Segment operating income	103,539	101,343	323,238	303,059
Corporate
Segment Reporting Information [Line Items]
Segment operating income	(53,873)	(62,360)	(196,872)	(219,131)
Segment operating income
Segment Reporting Information [Line Items]
Revenues	1,215,994	1,208,971	3,573,002	3,374,378
Segment operating income	290,651	289,889	840,764	790,661
Healthcare [Member] [Member]
Segment Reporting Information [Line Items]
Revenues	769,144	759,675	2,200,483	2,106,626
Segment operating income	175,399	175,778	497,233	482,487
Dental
Segment Reporting Information [Line Items]
Revenues	103,563	105,090	317,988	255,954
Segment operating income	$ 20,337	$ 23,096	$ 67,992	$ 65,607
Dental | Revenue Benchmark | Customer Concentration Risk
Segment Reporting Information [Line Items]
Concentration Risk, Percentage	47.20%	55.80%	43.80%	46.10%
Other foreign locations [Member]
Segment Reporting Information [Line Items]
Revenues	$ 314,645	$ 337,593	$ 930,400	$ 929,262
UNITED STATES
Segment Reporting Information [Line Items]
Revenues	883,390	851,292	2,589,472	2,383,039
UNITED KINGDOM
Segment Reporting Information [Line Items]
Revenues	17,959	20,086	53,130	62,077
Consumable revenues [Member] | Life Sciences
Segment Reporting Information [Line Items]
Revenues	55,610	61,096	172,587	179,380
Consumable revenues [Member] | Healthcare [Member] [Member]
Segment Reporting Information [Line Items]
Revenues	259,810	273,750	757,892	750,531
Sales Revenue, Services, Net [Member] | Life Sciences
Segment Reporting Information [Line Items]
Revenues	37,082	36,400	107,566	104,983
Sales Revenue, Services, Net [Member] | Healthcare [Member] [Member]
Segment Reporting Information [Line Items]
Revenues	282,108	268,711	823,747	785,586
Capital equipment revenues [Member] | Life Sciences
Segment Reporting Information [Line Items]
Revenues	28,581	30,412	99,095	97,343
Capital equipment revenues [Member] | Healthcare [Member] [Member]
Segment Reporting Information [Line Items]
Revenues	$ 227,226	$ 217,214	$ 618,844	$ 570,509

Shares and Preferred Shares Ord

Shares and Preferred Shares Ordinary Shares (Details)	3 Months Ended		9 Months Ended
	Dec. 31, 2022 $ / shares shares	Dec. 31, 2021 shares	Dec. 31, 2022 $ / shares shares		Dec. 31, 2021 shares	Dec. 31, 2022 EUR (€) shares
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted average shares outstanding - basic	99,716,000	100,038,000	99,922,000		96,679,000
Dilutive effect of share equivalents	450,000	788,000	0	[1]	823,000
Weighted average shares outstanding and share equivalents - diluted	100,166,000	100,826,000	99,922,000		97,502,000
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Preferred Stock, Shares Authorized						50,000,000
Common Stock, Par or Stated Value Per Share | $ / shares	$ 0.001		$ 0.001
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 0.001		$ 0.001
Deferred Ordinary Shares						25,000
Employee share option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of share options that are antidilutive	797,000	271,000	577,000		251,000
Euro Member Countries, Euro
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Par Value (Euros) of Deferred Ordinary Shares | €						€ 1
[1]The dilutive effect of share equivalents is excluded from the calculation of diluted earnings per share for the nine months ended December 31, 2022 due to our net loss for that period.

Shares and Preferred Shares Pre

Shares and Preferred Shares Preferred Shares (Details)	Dec. 31, 2022 $ / shares
Class of Stock [Line Items]
Preferred shares, par value	$ 0.001

Repurchases of Shares (Details)

Repurchases of Shares (Details) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Jul. 30, 2019	May 07, 2019
Equity, Class of Treasury Stock [Line Items]
Share repurchase program, number of shares authorized	$ 160,626		$ 300,000	$ 78,979
Shares repurchased during period, number	775,320
Aggregate value of shares repurchased pursuant to authorization	$ 148,306
Shares obtained in connection with share based compensation award programs	74,897	225,493
Payments for shares obtained in connection with share based compensation programs	$ 13,060	$ 27,628

Share-Based Compensation Shar_2

Share-Based Compensation Share-Based Compensation (Details) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended
	Jun. 30, 2021 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Item]
Remaining shares available for grant		2,798,121
Weighted-average assumptions used for options granted:
Risk-free interest rate		2.44%	1.10%
Expected life of options		5 years 10 months 24 days	5 years 10 months 24 days
Exptected dividend yield of stock		0.80%	0.95%
Expected volatility of stock		24.49%	24.27%
Estimated forfeiture rate		2.54%	2.85%
Summary of share option activity:
Outstanding at March 31, 2017		1,560,954
Granted		235,435
Exercised		(25,228)
Forfeited		(8,928)
Outstanding at June 30, 2017		1,762,233
Exercisable at June 30, 2017		1,137,168
Weighted average exercise price:
Outstanding at March 31, 2017 | $ / shares		$ 138.37
Granted | $ / shares		247.45
Exercised | $ / shares		51.70
Forfeited | $ / shares		205.25
Outstanding at June 30, 2017 | $ / shares		153.85
Exercisable at June 30, 2017 | $ / shares		$ 121.60
Average Remaining Contractual Term, Outstanding at June 30, 2017		6 years 4 months 24 days
Aggregate Intrinsic Value, Outstanding at June 30, 2017 | $		$ 77,486
Average Remaining Contractual Term, Exercisable at June 30, 2017		5 years 4 months 24 days
Aggregate Intrinsic Value, Exercisable at June 30, 2017 | $		$ 74,465
Non-vested stock options outstanding expected to vest		611,629
Ordinary shares, closing price | $ / shares		$ 184.69
Total intrinsic value of stock options exercised | $		$ 4,638	$ 43,425
Net cash proceeds from the exercise of stock options | $		$ 1,497	$ 6,789
Weighted average grant date fair value of stock option grants, per share | $ / shares		$ 50.72	$ 37.52
Summary of non-vested restricted share activity:
Unrecognized compensation cost related to nonvested share-based compensation granted | $		$ 72,008
Weighted Average Period For Total Compensation Expense Not Yet Recognized		2 years 1 month 6 days
Restricted Stock
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period		485,510
Weighted-Average Grant Date Fair Value, Non-vested at Beginning of Period | $ / shares		$ 157.37
Number of Restricted Shares, Granted		126,974
Weighted-Average Grant Date Fair Value, Granted | $ / shares		$ 225.07
Number of Restricted Shares, Vested		(146,056)
Weighted-Average Grant Date Fair Value, Vested | $ / shares		$ 126.98
Number of Restricted Shares, Canceled		(15,681)
Weighted-Average Grant Date Fair Value, Canceled | $ / shares		$ 181.75
Number of Restricted Shares, Non-vested at End of Period		450,747
Weighted-Average Grant Date Fair Value, Non-vested at End of Period | $ / shares		$ 186.24
Fair Value, Share-based Payment Awards, Other than Options | $		$ 20,237
Restricted Stock Units (RSUs)
Weighted average exercise price:
Weighted average grant date fair value of stock option grants, per share | $ / shares	$ 191.18
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period		33,677
Number of Restricted Shares, Granted		13,030
Number of Restricted Shares, Vested		(13,189)
Number of Restricted Shares, Canceled		(2,120)
Number of Restricted Shares, Non-vested at End of Period		31,398
Share-based Payment Arrangement, Expense | $	$ 18,545
Share-based Compensation Arrangement by Share-based Payment Award, Conversion Ratio	0.4262
Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Weighted Average Grant Date Fair Value Attributable to Pre-Acquisition Services | $	$ 18,173
Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Weighted Average Grant Date Fair Value | $	$ 53,607
RSUs Cantel
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period		45,722
Weighted-Average Grant Date Fair Value, Non-vested at Beginning of Period | $ / shares		$ 191.18
Number of Restricted Shares, Granted		0
Weighted-Average Grant Date Fair Value, Granted | $ / shares		$ 0
Number of Restricted Shares, Vested		(24,775)
Weighted-Average Grant Date Fair Value, Vested | $ / shares		$ 191.18
Number of Restricted Shares, Canceled		(4,507)
Weighted-Average Grant Date Fair Value, Canceled | $ / shares		$ 191.18
Number of Restricted Shares, Non-vested at End of Period	280,402	16,440
Weighted-Average Grant Date Fair Value, Non-vested at End of Period | $ / shares		$ 191.18
Unrecognized compensation cost related to nonvested share-based compensation granted | $		$ 2,319
Weighted Average Period For Total Compensation Expense Not Yet Recognized		9 months 18 days

Financial and Other Guarantee_2

Financial and Other Guarantees Financial and Other Guarantees (Details) $ in Thousands	9 Months Ended
	Dec. 31, 2022 USD ($)
Product Warranty Liability [Line Items]
Balance, March 31, 2017	$ 14,108
Warranties issued during the period	8,749
Settlement made during the period	(9,415)
Balance, June 30, 2017	$ 13,442

Derivatives and Hedging Fair Va

Derivatives and Hedging Fair Value of Derivatives, Balance Sheet Location (Details) $ in Thousands, € in Millions, £ in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2022 USD ($) lb	Dec. 31, 2021 USD ($)	Dec. 31, 2022 GBP (£)	Dec. 31, 2022 MXN ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 EUR (€)	Mar. 31, 2022 USD ($)
Prepaid & Other
Derivative [Line Items]
Asset derivatives							$ 842		$ 2,780
Liability derivatives							0		0
Accrued expenses and other
Derivative [Line Items]
Asset derivatives							0		0
Liability derivatives							$ 326		$ 198
Foreign currency forward contracts | Selling, general, and administrative expense
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax	$ 952	$ 1,707	$ 5,581	$ 4,279
Commodity swap contracts
Derivative [Line Items]
Derivative, notional amount, weight | lb			200,400
Commodity swap contracts | Cost of Sales [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax	$ (1,189)	$ (417)	$ 1,994	$ (1,110)
Mexican peso | Foreign currency forward contracts
Derivative [Line Items]
Derivative Asset, Notional Amount						$ 150
euro | Foreign currency forward contracts
Derivative [Line Items]
Derivative Asset, Notional Amount | €								€ 16.3
British pounds sterling | Foreign currency forward contracts
Derivative [Line Items]
Liability derivatives | £					£ 13

Derivatives and Hedging Gain (L

Derivatives and Hedging Gain (Loss) on Derivatives, Income Statement Location (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Foreign currency forward contracts | Selling, general, and administrative expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss) recognized in income	$ (952)	$ (1,707)	$ (5,581)	$ (4,279)
Commodity swap contracts | Cost of revenues
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss) recognized in income	$ 1,189	$ 417	$ (1,994)	$ 1,110

Fair Value Measurements Fair _2

Fair Value Measurements Fair Value Hierarchy (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2022
Reported Value Measurement [Member]
Assets:
Cash and cash equivalents		$ 259,371		$ 259,371		$ 348,320
Forward and swap contracts	[1]	842		842		2,780
Equity Securities, FV-NI	[2]	6,820		6,820		8,520
Investments		2,178		2,178		2,272
Liabilities:
Deferred compensation plans	[2]	955		955		1,240
Long term debt	[3]	3,061,575		3,061,575		3,088,356
Contingent consideration obligations		14,820		14,820		10,550
Foreign Currency Contracts, Liability, Fair Value Disclosure	[1]	326		326		198
Debt and Equity Securities, Gain (Loss)		342	$ (28)	(1,385)	$ 200
Contingent consideration obligations		14,820		14,820		10,550
Level 1
Assets:
Cash and cash equivalents		259,371		259,371		348,320
Forward and swap contracts		0		0		0
Equity Securities, FV-NI	[2]	6,820		6,820		8,520
Investments		2,178		2,178		2,272
Liabilities:
Deferred compensation plans	[2]	955		955		1,240
Long term debt	[3]	0		0		0
Contingent consideration obligations		0		0		0
Foreign Currency Contracts, Liability, Fair Value Disclosure		0		0		0
Level 2
Assets:
Cash and cash equivalents		0		0		0
Forward and swap contracts	[1]	842		842		2,780
Equity Securities, FV-NI		0		0		0
Investments		0		0		0
Liabilities:
Deferred compensation plans		0		0		0
Long term debt	[3]	2,693,782		2,693,782		2,991,680
Contingent consideration obligations		0		0		0
Foreign Currency Contracts, Liability, Fair Value Disclosure	[1]	326		326		198
Level 3
Assets:
Cash and cash equivalents		0		0		0
Forward and swap contracts		0		0		0
Equity Securities, FV-NI		0		0		0
Investments		0		0		0
Liabilities:
Deferred compensation plans		0		0		0
Contingent consideration obligations	[4]	14,820		14,820		10,550
Debt Instrument, Fair Value Disclosure	[3]	0		0		0
Foreign Currency Contracts, Liability, Fair Value Disclosure		$ 0		$ 0		$ 0
[1]The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates.[2] We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the "Interest and miscellaneous expense (income) line" of the Consolidated Statement of Income. During the third quarter and first nine months of fiscal 2023, we recorded gains (losses) of $(342) and $1,385, respectively, related to these investments. During the third quarter and first nine months of fiscal 2022, we recorded gains (losses) of $28 and $(200), respectively, related to these investments. We estimate the fair value of our debt using discounted cash flow analyses, based on estimated current incremental borrowing rates for similar types of borrowing arrangement s.

Fair Value Measurements Conting

Fair Value Measurements Contingent Consideration Rollforward (Details) - USD ($) $ in Thousands		9 Months Ended
		Dec. 31, 2022	Mar. 31, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration		$ 14,820	$ 10,550
Additions
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in contingent consideration		7,450
Contingent consideration gain loss [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in contingent consideration		(3,100)
Payments
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in contingent consideration		(60)
Foreign currency translation adjustment
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in contingent consideration		(20)
Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration	[1]	14,820	10,550
Fair value		$ 0	$ 0
[1]Contingent consideration obligations arise from business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and capture the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates

Fair Value Measurements Availab

Fair Value Measurements Available-for-sale securities (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]
Equity Securities, FV-NI, Gain (Loss)	$ (342)	$ 28	$ 1,385	$ (200)

Reclassifications out of Accu_3

Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands		3 Months Ended				9 Months Ended
		Dec. 31, 2022		Dec. 31, 2021		Dec. 31, 2022		Dec. 31, 2021		Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Mar. 31, 2021
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax		$ (364,163)		$ (136,878)		$ (364,163)		$ (136,878)		$ (598,148)	$ (209,808)	$ (105,733)	$ (61,243)
Other Comprehensive Income (Loss), Net of Tax		234,096		(30,063)		(154,007)		(72,363)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		(111)		(1,082)	[1]	(348)		(3,272)
Other Comprehensive (Loss) Income, Net of Tax, Portion Attributable to Parent		(233,985)		31,145		154,355		75,635
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax		1,359		(7,040)		1,359		(7,040)		1,332	1,276	(6,533)	(5,519)
Other Comprehensive Income (Loss), Net of Tax		138		575		431		1,751
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	[2]	(111)		(1,082)		(348)		(3,272)
Other Comprehensive (Loss) Income, Net of Tax, Portion Attributable to Parent		(27)		507		(83)		1,521
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax		(365,522)		(129,838)		(365,522)		(129,838)		$ (599,480)	$ (211,084)	$ (99,200)	$ (55,724)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax		233,958		(30,638)		(154,438)		(74,114)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		0	[1]	0		0	[1]	0	[1]
Other Comprehensive (Loss) Income, Net of Tax, Portion Attributable to Parent		$ (233,958)		$ 30,638		$ 154,438		$ 74,114
[1]The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income.[2]The amortization (gain) of defined benefit pension items is reported in the Interest and miscellaneous expense (income) line of our Consolidated Statements of Income.

Intangible Assets, Goodwill a_3

Intangible Assets, Goodwill and Other (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2022
Goodwill [Line Items]
Goodwill	$ 3,853,009		$ 3,853,009		$ 4,404,343
Goodwill, Acquired During Period			10,753
Goodwill impairment loss	0	$ 0	490,565	$ 0
Goodwill, Written off Related to Sale of Business Unit			(2,358)
Goodwill, Foreign Currency Translation Gain (Loss)			(91,252)
Goodwill, Purchase Accounting Adjustments			22,088
Applied Sterilization Technologies [Member]
Goodwill [Line Items]
Goodwill	1,376,203		1,376,203		1,432,858
Goodwill, Acquired During Period			0
Goodwill impairment loss			0
Goodwill, Written off Related to Sale of Business Unit			0
Goodwill, Foreign Currency Translation Gain (Loss)			(56,655)
Goodwill, Purchase Accounting Adjustments			0
Life Science Member [Member]
Goodwill [Line Items]
Goodwill	181,362		181,362		179,288
Goodwill, Acquired During Period			0
Goodwill impairment loss			0
Goodwill, Written off Related to Sale of Business Unit			0
Goodwill, Foreign Currency Translation Gain (Loss)			(1,073)
Goodwill, Purchase Accounting Adjustments			3,147
Dental
Goodwill [Line Items]
Goodwill	0		0		465,367
Goodwill, Acquired During Period			0
Goodwill impairment loss			490,565
Goodwill, Written off Related to Sale of Business Unit			0
Goodwill, Foreign Currency Translation Gain (Loss)			(15,367)
Goodwill, Purchase Accounting Adjustments			40,565
Healthcare
Goodwill [Line Items]
Goodwill	$ 2,295,444		2,295,444		$ 2,326,830
Goodwill, Acquired During Period			10,753
Goodwill impairment loss			0
Goodwill, Written off Related to Sale of Business Unit			(2,358)
Goodwill, Foreign Currency Translation Gain (Loss)			(18,157)
Goodwill, Purchase Accounting Adjustments			$ (21,624)

Uncategorized Items - ste-20221

Label	Element	Value
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents	us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	$ 348,320,000
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents	us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	$ 220,531,000